Boston Scientific Filterwire EZ
This article was originally published in The Gray Sheet
Executive Summary
Domestic launch of next-generation embolic protection filter system for use in angioplasty and stent treatment of diseased saphenous vein grafts is announced Aug. 23 following FDA 510(k) clearance. Building on the first-generation Filterwire EX, launched in the U.S. in June 2003, the EZ debuted overseas last September featuring an updated "suspended loop" filter support design to enhance deliverability and effectiveness, Boston Scientific claims. The 510(k) was supported by the 90-patient BLAZE multi-center clinical registry. Separately, the firm reports FDA market go-ahead for its Peripheral Cutting Balloon angioplasty system. Featuring longitudinally mounted microsurgical blades, the device is intended to treat blocked hemodialysis access grafts in end-stage renal disease patients. The system requires less pressure and trauma than conventional angioplasty, the firm says...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.